Dompe' Farmaceutici S.p.a.

Nykode Therapeutics Asa

Vaccibody As

Pier Adelchi Ruffini

Bjarne Bogen

Agnete Brunsvik Fredriksen

Marcello Allegretti

Laura Brandolini

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.

IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.

Homodimeric protein constructs

The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.

Growing community of inventors

Milan, Italy

Pier Adelchi Ruffini